IL-17 inhibitors for psoriasis

Seminars in Cutaneous Medicine and Surgery

Volumn 37, Issue 3, 2018, Pages 148-157

  Paek, So Yeon ^a,b   Frieder, Jillian ^a   Kivelevitch, Dario ^a   Menter, M Alan ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17B; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; IXEKIZUMAB; MONOCLONAL ANTIBODY; SECUKINUMAB; TH17 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; PROTEIN FAMILY; PSORIASIS; RELAPSE; SIDE EFFECT; TH17 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 85058007751     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.2018.051     Document Type: Article

References (57)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. doi: 10.1056/NEJMra0804595.
2. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. doi: 10.1038/nrdp.2016.82.
3. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302-309. doi: 10.1038/cmi.2012.15.
4. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6): 461-467.
5. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174-181. doi: 10.1016/j.it.2012.11.005.
6. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-150. doi: 10.1016/j.jaad.2013.12.036.
7. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Disc. 2012;11(10):763-776. doi: 10.1038/nrd3794.
8. Malakouti M, Brown GE, Wang E, Koo J, Levin EC. The role of IL-17 in psoriasis. J Dermatol Treat. 2015;26(1):41-44. doi: 10.3109/09546634.2013.879093.
9. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol. 2007;8(9):950-957. doi: 10.1038/ni1497.
10. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimune disease. Trends Immunol. 2011;32(9):395-401. doi: 10.1016/j.it.2011.06.007.
11. Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1-11. doi: 10.1016/j.jaut.2015.04.006.
12. Cosentyx (secukinumab) [package insert]. Switzerland: Novartis Pharmaceutical Corporation. 2016.
13. Novartis Pharmaceuticals Corporation [Advisory Committee Briefing Material for Cosentyx]. Switzerland.
14. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis -- results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi: 10.1056/NEJMoa1314258.
15. Griffiths C, Papp K, Zaldivar R, Gong Y, Fox T, Papavassilis C. Secukinumab shows efficacy in subjects regardless of previous exposure to biologic therapy: A pooled subanalysis from four phase 3 clinical trials in psoriasis (poster 1760). Poster presented at: 73rd AAD Annual Meeting. March 20-24, 2015, San Francisco, CA.
16. Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36. doi: 10.1016/j.jaad.2015.04.011.
17. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033-1042. doi: 10.1111/bjd.15706.
18. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018. doi: 10.1111/jdv.14878.
19. Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777-787. doi: 10.1111/bjd.13814.
20. Blauvelt A, Reich K, Tsai T, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-69. doi: 10.1016/j.jaad.2016.08.008.
21. Sitcherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024-1032. doi: 10.1111/bjd.15707.
22. Ohtsuki M, Morita A, Igarashi A, et al. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol. 2017;44(10):1105-1111. doi: 10.1111/1346-8138.13911.
23. Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033.
24. Reich K, Jazayeri S, Augustin M, Tao A, Milutinovich M. Secukinumab shows high and sustained efficacy in nail psoriasis: Week 80 results from the TRANSFIGURE study. J Am Acad Dermatol. 2017;76(6 suppl 1):AB232.
25. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80. doi: 10.1016/j.jaad.2016.07.058.
26. Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011-1017. doi: 10.1111/1346-8138.13306.
27. van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83-98. doi: 10.1016/j.jaad.2016.03.024.
28. Taltz™ (ixekizumab) [package insert]. FDA: Eli Lilly and Company, Indianapolis, IN. 2016.
29. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375(4):345-356. doi: 10.1056/NEJMoa1512711.
30. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551. doi: 10.1016/S0140-6736(15)60125-8.
31. Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, Reich K. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855-862. doi: 10.1016/j.jaad.2017.06.153.
32. 32. Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014-1023. doi: 10.1111/bjd.15666.
33. Armstong AW, Lynde CW, McBride SR, et al. Effect of Ixekizumab Treatment on Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016;152(6):661-669. doi: 10.1001/jamadermatol.2016.0269.
34. van de Kerkhof P, Guenter L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477-482. doi: 10.1111/jdv.14033.
35. Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28(4):282-287. doi: 10.1080/09546634.2016.1249820.
36. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686-1692. doi: 10.1111/jdv.14237.
37. Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355-362. doi: 10.1111/1346-8138.13622.
38. Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432-440. doi: 10.1016/j.jaad.2016.09.026.
39. Papp KA, Bachelez H, Blauvelt A, et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017;177(6):1537-1551. doi: 10.1111/bjd.15723.
40. Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab non-responders with plaque psoriasis: a multicenter retrospective study of interleukin (IL)-17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003.
41. Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448. doi: 10.1016/j.jaad.2016.10.027.
42. Siliq™ (brodalumab) [package insert]. Bridgewater: Valeant Pharmaceuticals North America LLC, NJ. 2017.
43. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi: 10.1056/NEJMoa1503824.
44. Papp K, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-286. doi: 10.1111/bjd.14493.
45. Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018. doi: 10.1111/jdv.14913.
46. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183-1190. doi: 10.1016/j.jaad.2014.08.039.
47. Chiricozzi A, Romanelli M, Saraceno R, Torres T. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15(12):1653-1659. doi: 10.1080/14740338.2016.1228872.
48. Singh S, Taylor C, Kornmehl H, Armstong AW. Psoriasis and suicidality: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425-440. doi: 10.1016/j.jaad.2017.05.019.
49. Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051.
50. Cohen AD, Dreiher J, Birkenfield S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561-565. doi: 10.1111/j.1468-3083.2008.03031.x.
51. Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383-394. doi: 10.1016/j. jaad.2017.06.043.
52. Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018;37(2S):S48-S51. doi: 10.12788/j.sder.2018.011.
53. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-493. doi: 10.1111/bjd.13348.
54. Gottlieb AB, Blauvelt A, Prinz JC, et al. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial. J Drugs Dermatol. 2016;15(10):1226-1234.
55. Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847-856. doi: 10.1111/jdv.14073.
56. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-409. doi: 10.1016/j.jaad.2015.05.013.
57. Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron G; Japanese UNCOVER-1 Study Group. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1). J Dermatol. 2017;44(11):1285-1290. doi: 10.1111/1346-8138.13927.